Skip to main content
OpenTrials

Clinical trial condition

Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified

Explore clinical trials studying Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified. Study availability and eligibility vary by location and protocol.

7 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified trial results

Recruiting

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

NCT03011814

Conditions
Folliculotropic Mycosis Fungoides, Hemic and Lymphatic Diseases, Immune System Diseases, +17 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Memorial Sloan-Kettering Cancer Center New York, United States
  • Thomas Jefferson University Hospital Philadelphia, Pennsylvania, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, Not Recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998

Conditions
Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, +35 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
View Trial Details

Related conditions